- Openwater raises $54 million in new funding from both new and existing investors, bringing total funding to $100 million.
- The company's platform combines light, sound, and semiconductor physics for cellular-level disease diagnosis and treatment.
- Preclinical and clinical studies show potential in reducing brain tumors and treating severe depression.
Medical technology company Openwater has raised $54 million in new funding from both new and existing investors, bringing the company's total funding to $100 million.
New and existing investors include Plum Alley Ventures, Khosla Ventures, BOLD Capital Partners, Esther Dyson, and Peter Gabriel.
The company announced plans to accelerate the commercialization of its hospital-grade technology platform, which integrates semiconductor physics, light, and sound to diagnose and treat diseases at the cellular level.
“As a brain tumor survivor, I’m not just developing technology; I’m fighting for my life and the lives of millions like me,” says Mary Lou Jepsen, Openwater’s founder and CEO. “We’ve shrunk brain tumors and treated depression using lower intensity sound waves than fetal ultrasounds.”
Openwater’s healthcare platform integrates high-resolution infrared imaging, precision-tuned ultrasound, and targeted electromagnetic fields, allowing for exceptional visualization, monitoring, and treatment of biological issues.
This technology can target and destroy cancer cells while leaving healthy cells unharmed, similar to how an opera singer's voice can shatter a specific wine glass without affecting others.
Promising outcomes from preclinical and clinical studies include the reduction of glioblastoma tumors in mice and the successful treatment of severe depression in humans.
Collaboration with institutions such as UCLA, the University of Arizona, the University of Pennsylvania, and Brown University has validated the technology's potential across a range of medical fields.
Edited by Harshajit Sarmah
Also Read:
Shailaja Pathak
